COVID-19: India's first intranasal vaccine by Bharat Biotech gets DCGI approval

DN Bureau

The Bharat Biotech on Tuesday got emergency use authorisation from the Drugs Controller General of India (DCGI) for the Intranasal Covid-19 vaccine. Read more on Dynamite News:

Representative image
Representative image


New Delhi: The Bharat Biotech on Tuesday got emergency use authorisation from the Drugs Controller General of India (DCGI) for the Intranasal Covid-19 vaccine. This will be India's first nasal vaccine for COVID-19. Union Minister of Health and Family Welfare Mansukh Mandaviya termed it a 'Big boost' to India's fight against Covid-19.

Read also: Bumper stock market listing for Dreamfolks Services; Read here

Also Read | COVID-19 vaccines of SII, Bharat Biotech approved for restricted use in emergency situation

He took to Twitter and said, "Big Boost to India's Fight Against COVID-19! Bharat Biotech's ChAd36-SARS-CoV-S COVID-19 (Chimpanzee Adenovirus Vectored) recombinant nasal vaccine approved by @CDSCO_INDIA_INF for primary immunization against COVID-19 in 18+ age group for restricted use in emergency situation."

"This step will further strengthen our collective fight against the pandemic. India has harnessed its science, R&D, and human resources in the fight against COVID-19 under PM @NarendraModi Ji's leadership," he added.

Also Read | ICMR: COVAXIN neutralises multiple variants of SARS-COV-2, double mutant strain

Read also: Rashmika Mandanna, Amitabh Bachchan's family entertainer 'GoodBye' trailer out now

He also said that we will defeat Covid-19 with a science-driven approach. "With the science-driven approach and Sabka Prayas, we will defeat COVID-19," he said. (ANI)










Related Stories